Adicet Bio Inc (ACET) Stock Price, Quote & News

Company Profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmun...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 503 9095

Website: www.adicetbio.com

Address:

131 Dartmouth Street, 3rd Floor, Boston, United States

pc247cz Jan. 14 at 1:30 PM

$ACET I expect PUMP before another offering will be pursued.

0 · Reply

Peterson28 Jan. 12 at 10:29 PM

$ACET Buying more everyday

1 · Reply

OHCF Jan. 12 at 8:39 PM

$ACET oooh reverse split. I don't like it.

0 · Reply

JohnTrack Jan. 7 at 6:21 PM

$ACET Provides Corporate Update and Highlights Expected 2026 Milestones https://www.rapidticker.com/news/acet-sec-filing-66a131

0 · Reply

Klamalsnn Jan. 7 at 12:48 PM

$ACET Update failed in Milestone delivery 26. postponemenz on all 2 Programms. Time to Leave

3 · Reply

_Emily_Johnson_ Jan. 7 at 5:41 AM

$ACET microcap biotech under the radar, tight coil, volume ignition can flip it into squeeze risk

0 · Reply

anachartanalyst Jan. 6 at 4:02 PM

$ACET https://anachart.com/wp-content/uploads/ana_temp/1767715304_soc-img.jpg

1 · Reply

PnLLogicX_1702 Jan. 6 at 11:33 AM

$ACET microcap biotech under the radar, tight coil, volume ignition can flip it into squeeze risk

0 · Reply

NEWBIGTECH Jan. 2 at 8:41 PM

$ACET funds moved to $SLS. 2 DRUGS, 20 + CANCERS for both. Look it up. @Sellaslife

0 · Reply

nnkr Dec. 31 at 6:57 PM

$ACET I'm in another biotech (RIGL) that did 10:1 RS in June 2024. It's tripled since then, so not every RS is bad for the company's future.

0 · Reply

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

Dec 26, 2025, 8:30 AM EST - 19 days ago

Adicet Bio Announces Reverse Stock Split

Nov 28, 2025, 2:23 PM EST - 6 weeks ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Nov 5, 2025, 4:01 PM EST - 2 months ago

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Oct 31, 2025, 4:59 PM EDT - 2 months ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 28, 2025, 7:00 AM EDT - 2 months ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

$Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)$

Oct 16, 2025, 7:00 AM EDT - 3 months ago

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Oct 7, 2025, 12:35 PM EDT - 3 months ago

Adicet Bio, Inc. - Special Call

Oct 7, 2025, 11:05 AM EDT - 3 months ago

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2

Oct 7, 2025, 7:01 AM EDT - 3 months ago

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Oct 7, 2025, 6:45 AM EDT - 3 months ago

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Sep 2, 2025, 7:00 AM EDT - 4 months ago

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 7, 2025, 4:01 PM EDT - 5 months ago

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 5, 2025, 7:00 AM EDT - 5 months ago

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Jul 24, 2025, 7:00 AM EDT - 6 months ago

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

May 21, 2025, 4:00 PM EDT - 8 months ago

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

May 6, 2025, 4:01 PM EDT - 9 months ago

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 30, 2025, 7:00 AM EDT - 9 months ago

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Apr 28, 2025, 4:30 PM EDT - 9 months ago

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Apr 17, 2025, 7:00 AM EDT - 9 months ago

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Mar 31, 2025, 5:12 PM EDT - 10 months ago

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 7:00 AM EDT - 10 months ago

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 6, 2025, 4:01 PM EST - 11 months ago

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Mar 3, 2025, 7:00 AM EST - 11 months ago

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Feb 27, 2025, 7:00 AM EST - 11 months ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

$Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement$

Feb 5, 2025, 7:10 AM EST - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Jan 29, 2025, 7:00 AM EST - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Jan 8, 2025, 4:10 PM EST - 1 year ago

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Dec 19, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Dec 18, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Nov 18, 2024, 4:00 PM EST - 1 year ago

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Nov 18, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Nov 16, 2024, 9:00 AM EST - 1 year ago

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Nov 6, 2024, 4:00 PM EST - 1 year ago

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 5, 2024, 7:00 AM EST - 1 year ago

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Nov 1, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in Upcoming Investor Conferences

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Sep 30, 2024, 4:30 PM EDT - 1 year ago

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Sep 19, 2024, 7:00 AM EDT - 1 year ago

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Aug 27, 2024, 4:00 PM EDT - 1 year ago

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

May 29, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

May 14, 2024, 4:01 PM EDT - 1 year ago

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

May 14, 2024, 10:00 AM EDT - 1 year ago

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

pc247cz Jan. 14 at 1:30 PM

$ACET I expect PUMP before another offering will be pursued.

0 · Reply

Peterson28 Jan. 12 at 10:29 PM

$ACET Buying more everyday

1 · Reply

OHCF Jan. 12 at 8:39 PM

$ACET oooh reverse split. I don't like it.

0 · Reply

JohnTrack Jan. 7 at 6:21 PM

$ACET Provides Corporate Update and Highlights Expected 2026 Milestones https://www.rapidticker.com/news/acet-sec-filing-66a131

0 · Reply

Klamalsnn Jan. 7 at 12:48 PM

$ACET Update failed in Milestone delivery 26. postponemenz on all 2 Programms. Time to Leave

3 · Reply

_Emily_Johnson_ Jan. 7 at 5:41 AM

$ACET microcap biotech under the radar, tight coil, volume ignition can flip it into squeeze risk

0 · Reply

anachartanalyst Jan. 6 at 4:02 PM

$ACET https://anachart.com/wp-content/uploads/ana_temp/1767715304_soc-img.jpg

1 · Reply

PnLLogicX_1702 Jan. 6 at 11:33 AM

$ACET microcap biotech under the radar, tight coil, volume ignition can flip it into squeeze risk

0 · Reply

NEWBIGTECH Jan. 2 at 8:41 PM

$ACET funds moved to $SLS. 2 DRUGS, 20 + CANCERS for both. Look it up. @Sellaslife

0 · Reply

nnkr Dec. 31 at 6:57 PM

$ACET I'm in another biotech (RIGL) that did 10:1 RS in June 2024. It's tripled since then, so not every RS is bad for the company's future.

0 · Reply

tr1llA Dec. 31 at 4:51 PM

$ACET nice up so far

0 · Reply

pc247cz Dec. 31 at 4:13 PM

$ACET is leaving the station 🫡

0 · Reply

pc247cz Dec. 31 at 3:11 PM

$INBS Congrats. $ACET could be next. And $AKTX is undisovered gem.

0 · Reply

smartmoney43 Dec. 31 at 12:46 AM

$ACET tnxp went from 7 to 60 in 6 months. I guess anything is possible here

0 · Reply

Ultra48 Dec. 30 at 7:08 PM

$ACET This is a crap company run by the brain dead. Good luck to those with some confidence to stick around.

0 · Reply

BullDonald Dec. 30 at 4:55 PM

$ACET Say you are trash with out saying it. Bro wants you to use his screener that shows 1600% for ACET 🤣

0 · Reply

qfcjhn Dec. 30 at 4:18 PM

$IXHL I believe in stock splits. Many biotech companies do this when compliance delays with a price above $1 are difficult to obtain. Just today, for example, I have $ACET, which was in the same situation as $IXHL, which ended up doing a split... But it's not a big deal if that happens; on the contrary, it eases the atmosphere in the medium term.

0 · Reply

stockanalysis_ Dec. 30 at 2:18 PM

Premarket Gainers: $BIYA $ORIS $APVO $ACET $ILAG Save this screener: https://stockanalysis.com/markets/premarket/gainers/?ref=saveontrading

0 · Reply

OnTheFringe Dec. 30 at 2:12 PM

$ACET I'm seeing a nice 6% premarket move, $8.37

0 · Reply

Iorgi Dec. 30 at 2:10 PM

$ACET That's usually how splits are done. The stock is halted until regular market open at 9:30 AM Eastern Time, at which time the stock will open at it's newly adjusted price, $7.87 or whatever the market price happens to be at time of market open.

1 · Reply

OKUltra Dec. 30 at 1:37 PM

$ACET Let the games begin. Now that ACET is compliant and RS is done the officers i.e.insiders of ACET will use this as their personal ATM. Watch for the creation of new shares and a significant price drop. These RS procedures usually crush share holders other than insiders.

1 · Reply

Zgod Dec. 30 at 1:36 PM

$ACET sad to say I’m out, should’ve sold at $1. More opportunities elsewhere. Good luck to longs

0 · Reply

Market Cap	74.81M
Revenue (ttm)	0.00
Net Income (ttm)	-117.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	112,700
Avg Vol	169,634
Day's Range	N/A - N/A
Shares Out	9.58M
Stochastic %K	44%
Beta	1.60
Analysts	Strong Sell
Price Target	$96.33